内科

目的探讨左西孟旦注射液联合谷红注射液治疗慢性心力衰竭患者的临床疗效。方法选取2019年1月至2020年12月我院收治的慢性心力衰竭患者240例，采取随机数字法分为两组，每组120例。对照组患者给予左西孟旦注射液治疗，观察组患者给予左西孟旦注射液联合谷红注射液治疗。比较两组患者的临床疗效；比较两组患者治疗后的心功能、血清白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、脑钠肽（BNP）水平以及不良反应发生情况。结果治疗2个月，观察组患者的治疗总有效率（98.3%）显著高于对照组（92.5%），差异有统计学意义（P＜0.05）。治疗前，两组患者左室舒张末期内径（LVEDD）、左心射血分数（LVEF）、左室收缩末期内径（LVESD）比较，差异无统计学意义（P＞0.05）；治疗2个月后，两组患者的LVEDD、LVEF、LVESD均得到改善，观察组患者的改善情况显著优于对照组，差异有统计学意义（P＜0.05）。治疗前，两组患者的IL-6、TNF-α、BNP水平比较，差异无统计学意义（P＞0.05）；治疗2个月后，两组患者的IL-6、TNF-α、BNP水平均显著降低，观察组患者的水平显著低于对照组，差异有统计学意义（P＜0.05）。治疗前，两组患者症状积分比较，差异无统计学意义（P＞0.05）；治疗2个月后，两组患者的症状积分均显著降低，观察组患者的积分显著低于对照组，差异有统计学意义（P＜ 0.05）。治疗过程中，观察组患者的不良反应发生率（1.67%）与对照组（0.83%）比较，差异无统计学意义（P＞0.05）。结论左西孟旦注射液联合谷红注射液治疗慢性心力衰竭患者临床疗效显著，能够有效改善患者心功能，显著降低炎症因子水平，明显缓解临床症状，促进患者康复。

ObjectiveTo investigate the clinical efficacy of levosimendan injection combined with Guhong injection in the treatment of patients with chronic heart failure. MethodsA total of 240 patients with chronic heart failure admitted to our hospital from January 2019 to December 2020 were randomly divided into two groups, with 120 cases in each group. The patients in the control group were treated with levosimendan injection, whereas the patients in the observation group were treated with levosimendan injection combined with Guhong injection. Clinical efficacy of the two groups was compared; the cardiac function, and serum interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), brain natriuretic peptide (BNP) levels and the occurrence of adverse reactions were compared between the two groups. ResultsAfter two months of treatment, the total effective rate of the observation group (98.3%) was significantly higher than that of the control group (92.5%), with a statistically significant difference (P＜0.05). Before treatment, there were no statistically significant differences in left ventricular end-diastolic dimension (LVEDD), left ventricular ejection fraction (LVEF) and left ventricular end-systolic dimension (LVESD) between the two groups (P＞0.05). After two months of treatment, LVEDD, LVEF and LVESD improved in both groups, and the observation group yielded a superior improvement as compared with the control group, with statistically significant differences (P＜0.05). Before treatment, there were no statistically significant differences in the level of IL-6, TNF-α and BNP between the two groups (P＞ 0.05). After two months of treatment, The levels as below significantly decreased in both groups, and the levels of IL-6, TNF-α and BNP in the observation group were significantly lower than those in the control group, with statistically significant differences (P＜0.05). Before treatment, there was no statistically significant difference in symptom scores between the two groups (P＞0.05). After two months of treatment, the symptom scores of the two groups decreased significantly, and the scores of the observation group were significantly lower than those of the control group, with statistically significant differences (P＜0.05). During the treatment, there was no statistically significant difference in the incidence of adverse reactions between the observation group (1.67%) and the control group (0.83%) (P＞0.05). ConclusionLevosimendan injection combined with Guhong injection in the treatment of patients with chronic heart failure has prominently clinical efficacy, which can effectively improve the cardiac function, decrease the levels of inflammatory factors, alleviate the clinical symptoms, and promote the rehabilitation of patients.